Tscan Therapeutics Ownership
| TCRX Stock | USD 1.67 0.06 3.73% |
Shares in Circulation | First Issued 2020-03-31 | Previous Quarter 118.7 M | Current Value 120.8 M | Avarage Shares Outstanding 49.9 M | Quarterly Volatility 38.8 M |
Tscan |
Tscan Stock Ownership Analysis
About 91.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.38. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tscan Therapeutics recorded a loss per share of 1.14. The entity last dividend was issued on the 13th of September 1970. TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. Tscan Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 115 people. To find out more about Tscan Therapeutics contact the company at 857 399 9500 or learn more at https://www.tscan.com.Besides selling stocks to institutional investors, Tscan Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Tscan Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Tscan Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Tscan Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Less than 1% of Tscan Therapeutics are currently held by insiders. Unlike Tscan Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Tscan Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Tscan Therapeutics' insider trades
Tscan Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Tscan Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tscan Therapeutics backward and forwards among themselves. Tscan Therapeutics' institutional investor refers to the entity that pools money to purchase Tscan Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Aberdeen Group Plc | 2024-12-31 | 883.7 K | State Street Corp | 2024-12-31 | 800.9 K | Dc Funds, Lp | 2024-12-31 | 630 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 412.9 K | Northern Trust Corp | 2024-12-31 | 322.1 K | Dimensional Fund Advisors, Inc. | 2024-12-31 | 280 K | Tocqueville Asset Management L.p. | 2024-12-31 | 260.9 K | Goldman Sachs Group Inc | 2024-12-31 | 160.7 K | Bank Of America Corp | 2024-12-31 | 150.1 K | Ecor1 Capital, Llc | 2024-12-31 | 5 M | Blackrock Inc | 2024-12-31 | 5 M |
Tscan Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tscan Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tscan Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tscan Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tscan Therapeutics Outstanding Bonds
Tscan Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tscan Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tscan bonds can be classified according to their maturity, which is the date when Tscan Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Tscan Stock Analysis
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.